Highlights bioXXmed AG

Equities

T5O

DE000A0KFRJ1

Delayed Xetra Other stock markets 11:36:19 2024-05-02 am EDT			5-day change	1st Jan Change
0.468 ^EUR	-3.70%		-0.43%	+4.93%

2023	BioXXmed AG Reports Earnings Results for the Half Year Ended June 30, 2023	CI
2023	BioXXmed AG Reports Earnings Results for the Full Year Ended December 31, 2022	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioXXmed AG Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-30	CI
BioXXmed AG Reports Earnings Results for the Full Year Ended December 31, 2022	23-06-27	CI
CytoTools AG Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-31	CI
CytoTools AG Reports Earnings Results for the Full Year Ended December 31, 2021	22-06-30	CI
CytoTools Reports Progress of DermaPro(R) Phase III Study in Europe and Provides Operational Status Update	21-09-29	CI
Lordstown Motors : says hedge fund may buy up to $400 mln of its stock	21-07-26	RE
Cytotools Ag Reports Earnings Results for the Full Year Ended December 31, 2020	21-06-30	CI
CytoTools AG's Licensing Partner Centaur Pharmaceuticals Inc. Receives Tentative Approval for Woxheal(R) in Kenya, Africa	21-06-21	CI
CytoTools : Joins Activoris Medizintechnik To Develop Inhalation Therapy	21-04-26	MT
CytoTools Signs Collaboration Agreement to Develop Inhalation Therapy for Viral Infections Such as COVID-19 and Influenza	21-04-26	CI
CytoTools AG and Centaur Pharmaceuticals Achieves A Good Start to the Marketing of Its Active Ingredient for the Treatment of Diabetic Foot Syndrome in India	21-02-22	CI
CyTotools Receives Confirmation of Efficacy of DPCOL Also Against Influenza Viruses	20-12-21	CI
CytoTools AG Receives the Preliminary Results of the Test Series with the Active Substance DPOCL	20-11-13	CI
CytoTools Starts Phase III Study of DermaPro in Europe	20-10-29	CI
CytoTools AG Secures Financing of the Phase III Study	20-10-06	CI
CytoTools Examines the Effectiveness of Its Patented Active Substance DPOCL in COVID-19 Infections	20-09-17	CI
CytoTools AG Partner Centaur Pharmaceuticals Pvt Ltd Starts Marketing the Active Substance DPOCL in India	20-09-03	CI
Cytotools Ag Reports the Treatment of the Last Patients in the Phase II Trial of Dermapro Carried by DermaTools Biotech GmbH	19-07-04	CI
CytoTools AG Reports on the Expected Successful Course of the Current Dosage Determination Trial of DermaPro in Phase II	19-03-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

As early as today, start finding the best investment opportunities!

Optimize my profits

fermer